Transitioning Therapeutic Antibodies in Oncology from Intravenous to Hyaluronidase-Facilitated Subcutaneous Administration [0.03%]
从静脉注射转换为透明质酸酶介导的皮下给药在肿瘤学治疗抗体中的应用
Xu Steven Xu
Xu Steven Xu
Intravenous (IV) infusion remains the predominant delivery route for oncology monoclonal antibodies, but it requires prolonged chair time and substantial infusion-unit resources. Hyaluronidase-facilitated subcutaneous (SC) formulations aim ...
Correction: Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28‑Joint C‑Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis [0.03%]
使用疾病活动度评分(DAS28-CRP)和绝对中性粒细胞计数校正sarilumab的群体药代动力学-药效学关系：类风湿关节炎患者的疗效分析
Lei Ma,Christine Xu,Anne Paccaly et al.
Lei Ma et al.
Published Erratum
Clinical pharmacokinetics. 2026 Jul 10. DOI:10.1007/s40262-026-01656-y 2026
Clinical Pharmacokinetics and Pharmacodynamics of the IL-1 Receptor Antagonist Anakinra: A Systematic Review [0.03%]
阿那白滞素的临床药动学和药效学：系统评价
Jia Li,Megan Clark,David K Metz et al.
Jia Li et al.
Background and objective: Anakinra, an interleukin-1 receptor antagonist (IL-1Ra), has been used clinically for over 20 years, with growing interest in repurposing it across diverse indications. However, clinical dosing s...
Physiologically Based Pharmacokinetic (PBPK) Modeling of Antidepressants: A Scoping Review of Existing Models, Applications, and Software Tools [0.03%]
基于生理的药代动力学(PBPK)在抗抑郁药物中的模型、应用及软件工具构建：范围性综述
Rebecca Leyla Huber,Oliver Scherf-Clavel
Rebecca Leyla Huber
Physiologically based pharmacokinetic models are a valuable tool for simulating antidepressant pharmacokinetics in patient groups that are often underrepresented in clinical trials. Clinical data on antidepressant use in vulnerable populati...
Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review [0.03%]
多替拉韦的群体药代动力学模型的叙述性综述
Émilie Pilote,Nancy L Sheehan,Amélie Marsot
Émilie Pilote
Dolutegravir-based regimens are part of the preferred regimens in all populations living with HIV, but dolutegravir's pharmacokinetics can vary greatly with factors such as drug-drug interactions (DDIs) and age. For example, DDIs between do...
Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics [0.03%]
曲线下面积的部分区域：药动学中的一个启示性故事
Maheshwari Periyasamy,Mirunalini Ravichandran
Maheshwari Periyasamy
Bioequivalence studies are important for a generic drug to enter the market. These studies mainly examine various pharmacokinetic parameters like Cmax, AUC0-T and AUC0-∞. But at times, these parameters might not be sufficient to pick up es...
Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model [0.03%]
基于肺部群体最小PBPK模型的取样设计研究
Haini Wen,Muhammad Waqas Sadiq,Markus Fridén et al.
Haini Wen et al.
Background: Understanding intrapulmonary pharmacokinetics (PK) following inhalation remains a significant challenge in drug development and repurposing. Current lung sampling methods include bronchoalveolar lavage (BAL), ...
Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing [0.03%]
单次和多次口服甲基泼尼松龙后的血浆和尿药动学特征重现：在体育药物检测中的意义
Sergi Coll,Claudia Bressan,Núria Monfort et al.
Sergi Coll et al.
Background: The pharmacokinetic profiles of methylprednisolone (MP) in plasma and urine were evaluated after single and multiple oral doses. MP is prohibited in sports competitions when administered systemically (oral, in...
ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma [0.03%]
ALBI分级决定日本肝细胞癌患者仑伐替尼药代动力学、疗效和不良反应的因素
Kosuke Suzuki,Yumi Otoyama,Natsumi Matsumoto et al.
Kosuke Suzuki et al.
Background and objective: The doses of lenvatinib for patients with hepatocellular carcinoma (HCC) are determined using the Child-Pugh classification and body weight. Because lenvatinib is highly bound to plasma albumin (...
Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer [0.03%]
定量药理学证实了ribociclib在早期乳腺癌中的剂量合理性
Yan Ji,Craig Wang,Francois Pierre Combes et al.
Yan Ji et al.
Background and objective: Ribociclib was recently approved for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (EBC) at the starting dose of 400 mg orally o...